Inflammation in Lung Cancer Patients with Clonal Hematopoiesis
Author Information
Author(s): Sim Hyungtai, Park Hyun Jung, Park Geun-Ho, Kim Yeon Jeong, Park Woong-Yang, Lee Se-Hoon, Choi Murim
Primary Institution: Seoul National University College of Medicine
Hypothesis
What is the impact of clonal hematopoiesis on the response to immunotherapy in non-small cell lung cancer patients?
Conclusion
Clonal hematopoiesis prevalence is higher in lung cancer patients, particularly in squamous cell carcinoma, but it has minimal impact on immunotherapy response.
Supporting Evidence
- Clonal hematopoiesis was found in 44 out of 100 lung cancer patients compared to 5 out of 42 controls.
- Lung squamous cell carcinoma patients had a higher burden of larger clones compared to lung adenocarcinoma patients.
- Single-cell RNA sequencing revealed significant enrichment of inflammatory pathways in myeloid cells of patients with high clonal hematopoiesis.
Takeaway
This study found that many lung cancer patients have a specific blood condition called clonal hematopoiesis, which is linked to inflammation but doesn't really change how well their treatment works.
Methodology
Blood samples were collected from 100 metastatic NSCLC patients for sequencing and analysis of clonal hematopoiesis and single-cell RNA sequencing.
Potential Biases
The cohort was biased towards older ages and higher smoking prevalence, which are known factors affecting clonal hematopoiesis.
Limitations
The study cohort had differences in age and smoking status compared to controls, which may confound results.
Participant Demographics
100 metastatic NSCLC patients, with a higher prevalence of smoking and older age compared to controls.
Statistical Information
P-Value
0.01
Statistical Significance
p = 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website